Scholarlink

Several reviews have enumerated the plethora of drug trials aimed at improving negative symptoms and/or cognitive performance in patients affected by schizophrenia (Sabe et al. Neurosci Biobehav Rev 144: 104979, 2023). The aim of this chapter is to highlight two of the reasons for the high rate of failures in these indications and to suggest potential remedies: (a) reduce heterogeneity of patients recruited for the trials by improving sample stratification and (b) employ monotherapy rather than add-on trial design.

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Methodologic Considerations on Developing Drugs for Negative Symptoms and Cognitive Impairment in Schizophrenia

  • 章节

  • 发表日期：

    2025年

查看全文
  • Michael Davidson,
  • Jay Saoud,
  • Remy Luthringer

摘要

Several reviews have enumerated the plethora of drug trials aimed at improving negative symptoms and/or cognitive performance in patients affected by schizophrenia (Sabe et al. Neurosci Biobehav Rev 144: 104979, 2023). The aim of this chapter is to highlight two of the reasons for the high rate of failures in these indications and to suggest potential remedies: (a) reduce heterogeneity of patients recruited for the trials by improving sample stratification and (b) employ monotherapy rather than add-on trial design.